Can Stem Cells Help With Lymphedema?

Lymphedema — the chronic limb swelling that follows damage to the lymphatic system, most often after cancer treatment — has no cure and no drug therapy, which has pushed researchers to ask whether stem cells could rebuild damaged lymphatic vessels. This article walks through the actual human trial record: a small early safety study with encouraging symptom relief, a systematic review of promising but inconsistent preclinical data, and — critically — the one real randomized, placebo-controlled trial, which found no objective benefit. It explains why that negative result matters and why no cell therapy is approved or proven for lymphedema today.

What Causes Lymphedema and Who It Affects

The lymphatic system drains excess fluid, proteins, and immune cells from tissue back into the bloodstream. When that drainage is damaged or blocked, fluid builds up, causing chronic swelling, heaviness, skin thickening, and a lasting infection risk. Primary lymphedema is rare and inherited; secondary lymphedema, the far more common form, follows damage to an otherwise normal system — most often the lymph node removal and radiation used to treat cancer, per a patient-health overview. Breast cancer treatment is the leading cause in developed countries: a 2013 systematic review and meta-analysis by DiSipio and colleagues in The Lancet Oncology found that roughly one in five treated women (21.4%) develop arm lymphedema, with risk highest after full axillary lymph node dissection and radiation.

Lymphedema is lifelong once established. Standard care — compression garments, manual lymphatic drainage, targeted exercise, and, in severe cases, surgery — can meaningfully ease symptoms, but none of it restores normal lymphatic function, which is why regenerative approaches have drawn research interest.

How It's Thought to Work

The rationale rests on two ideas. Mesenchymal stem cells — usually harvested from a patient's own fat as a mixture called adipose-derived regenerative cells (ADRCs) — are thought to secrete growth factors, including VEGF-C, that stimulate lymphangiogenesis (new lymphatic capillary growth) in lab and animal studies. And in the procedure tested most in humans, ADRCs are injected with a fat graft ("lipotransfer") into the scarred tissue of the affected limb, on the theory that releasing that scarring might ease the blockage trapping fluid. It's biologically plausible — but plausibility isn't proof, and that gap is where this research has struggled.

What the Evidence Shows

The human evidence follows an instructive arc: early promise, scaled up, then a sobering result. The first real signal came from a 2017 open-label feasibility study by Toyserkani and colleagues in Stem Cells Translational Medicine, treating ten women with breast cancer-related lymphedema using ADRCs plus fat grafting. With no control group, firm efficacy conclusions weren't possible, but patients reported real relief: median self-reported arm heaviness fell from 5.5 to 2.5 (0–10 scale) at six months. Objective arm-volume measurements, however, showed only a small reduction significant at one month but not sustained at three or six. The procedure was well tolerated.

A broader 2021 systematic review in Stem Cell Research & Therapy (Lafuente et al.) pooled 20 studies — six clinical, fourteen preclinical — and reported an overall positive effect of cell-based therapies on edema, lymphatic capillary density, and tissue fibrosis. Encouraging across the field, but the authors flagged substantial heterogeneity and called explicitly for rigorous, blinded, randomized trials before drawing clinical conclusions.

That trial has now been done, and it's the most important data point here. The same Danish group ran a randomized, double-blinded, placebo-controlled Phase II trial — Jørgensen et al., Plastic and Reconstructive Surgery (2024) — enrolling 80 women with persistent lymphedema: 39 received ADRCs with lipotransfer, 41 received an identical-seeming saline placebo. At one year, there was no significant objective difference in arm volume between groups, and both groups reported significant subjective improvement — suggesting the earlier study's benefit may have been placebo or procedural, not the cells. The authors concluded ADRCs and lipotransfer "should not be recommended" for this use today, leaving open whether different dosing or earlier treatment could still help.

Who Might Be a Candidate

Stem cell therapy is not a validated treatment for anyone with lymphedema today. The research points mainly to:

• People with persistent, disabling secondary lymphedema who have already tried standard compression and lymphatic-drainage care without adequate relief, and are considering an academic, registered clinical trial rather than a commercial clinic
• Researchers and patients interested in whether different cell doses, repeat dosing, or earlier-stage treatment — none tested in the negative trial above — might still show benefit

Bottom Line

Lymphedema research illustrates something worth sitting with: a therapy that looked promising in an early, uncontrolled study did not hold up once tested properly, with blinding and a placebo arm. Adipose-derived stem cells combined with fat grafting appear safe short-term but have not been shown, in the best trial available, to objectively reduce lymphedema beyond a placebo procedure. No stem cell therapy is FDA-approved for lymphedema, and any clinic marketing one as a cure is making a claim the evidence doesn't support. The underlying science of lymphangiogenesis remains active and legitimate, and future trials testing different doses or timing could still change this picture — but today, compression-based and surgical lymphatic care remain the only treatments with proven, durable benefit.